Our top pick for
VEON Ltd is a telecom services business based in the US. VEON shares (VEON) are listed on the NASDAQ and all prices are listed in US Dollars. VEON employs 43,639 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$2.19|
|52-week range||$1.20 - $2.38|
|50-day moving average||$2.20|
|200-day moving average||$1.89|
|Wall St. target price||$2.56|
|Dividend yield||$0.15 (6.91%)|
|Earnings per share (TTM)||$-0.22|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-19)||-5.60%|
|1 month (2021-09-24)||2.34%|
|3 months (2021-07-26)||28.82%|
|6 months (2021-04-26)||24.43%|
|1 year (2020-10-26)||71.09%|
|2 years (2019-10-25)||-9.88%|
|3 years (2018-10-26)||2.84|
|5 years (2016-10-26)||3.17|
Valuing VEON stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of VEON's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
VEON's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.9 billion.
The EBITDA is a measure of a VEON's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$8 billion|
|Operating margin TTM||19.3%|
|Gross profit TTM||$6.1 billion|
|Return on assets TTM||6.58%|
|Return on equity TTM||-23.57%|
|Market capitalisation||$3.8 billion|
TTM: trailing 12 months
There are currently 50.3 million VEON shares held short by investors – that's known as VEON's "short interest". This figure is 3% down from 51.8 million last month.
There are a few different ways that this level of interest in shorting VEON shares can be evaluated.
VEON's "short interest ratio" (SIR) is the quantity of VEON shares currently shorted divided by the average quantity of VEON shares traded daily (recently around 11.6 million). VEON's SIR currently stands at 4.33. In other words for every 100,000 VEON shares traded daily on the market, roughly 4330 shares are currently held short.
However VEON's short interest can also be evaluated against the total number of VEON shares, or, against the total number of tradable VEON shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case VEON's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 VEON shares in existence, roughly 30 shares are currently held short) or 0.0554% of the tradable shares (for every 100,000 tradable VEON shares, roughly 55 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against VEON.
Find out more about how you can short VEON stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like VEON.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 56.57
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and VEON's overall score of 56.57 (as at 12/31/2018) is pretty good – landing it in it in the 38th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like VEON is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 52.67/100
VEON's environmental score of 52.67 puts it squarely in the 28th percentile of companies rated in the same sector. This could suggest that VEON is doing better than many of its peers in terms of its environmental impact, and so perhaps exposed to a slightly lower level of risk.
Social score: 55.46/100
VEON's social score of 55.46 puts it squarely in the 57th percentile of companies rated in the same sector. This could suggest that VEON is pretty average in terms of looking after its workforce and social impact.
Governance score: 65.15/100
VEON's governance score puts it squarely in the 34th percentile of companies rated in the same sector. That could suggest that VEON is impressive in terms of responsible leadership, and exposed to a lower level of risk.
Controversy score: 4/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. VEON scored a 4 out of 5 for controversy – the second-lowest score possible, reflecting that VEON has a damaged public profile.
|Total ESG score||56.57|
|Total ESG percentile||37.66|
|Environmental score percentile||28.4|
|Social score percentile||57.38|
|Governance score percentile||33.54|
|Level of controversy||4|
We're not expecting VEON to pay a dividend over the next 12 months.
VEON's shares were split on a 5:1 basis on 21 August 2007. So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your VEON shares – just the quantity. However, indirectly, the new 80% lower share price could have impacted the market appetite for VEON shares which in turn could have impacted VEON's share price.
Over the last 12 months, VEON's shares have ranged in value from as little as $1.2 up to $2.38. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while VEON's is 1.3275. This would suggest that VEON's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
VEON Ltd. , through its subsidiaries, provides mobile and fixed-line telecommunications services. It offers voice, data, and other telecommunication services through a range of wireless, fixed, and broadband internet services. The company provides value added services, including short messages, multimedia messages, caller number identification, call waiting, data transmission, mobile internet, downloadable content, mobile finance services, machine-to-machine, and other services; national and international roaming services; wireless internet access and mobile financial services; and mobile bundles and call completion services. It also offers fixed-line telecommunication services, such as voice, data, internet, and value added services for corporations, operators, and consumers, as well as sells equipment and accessories. The company provides its services under the Beeline, Kyivstar, Jazz, Djezzy, and banglalink brands in Russia, Pakistan, Algeria, Uzbekistan, Ukraine, Bangladesh, Kazakhstan, Kyrgyzstan, and Georgia. It serves approximately 210 million customers.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.